A Novel Tumor Antigen and Foxp3 Dual-Targeting Tumor Cell Vaccine Enhances the Immunotherapy in a Murine Model of Renal Cell Carcinoma
Annual rept. 15 Sep 2013-14 Sep 2014
HEALTH RESEARCH INC BUFFALO NY
Pagination or Media Count:
During the past year I have generated Foxp3-over expressing RENCA cells, as the source of candidate dual targeting tumor cells vaccine. We have performed controlled vaccine therapy in RENCA model in three different schedules. When applied in a pre-vaccine schedule, RENCA and RENCA Foxp3 tumor cell vaccine efficiently prevented or inhibited orthotopic tumor growth. In an intervention schedule setting, RENCA Foxp3 tumor cell vaccine was superior to the RENCA tumor cell vaccine, and significantly reduced tumor growth, as compared to the vehicle and RENCA vaccine treated groups. In addition, the RENCA Foxp3 vaccine had activity to reduce number of T regulatory cells Tregs in tumor infiltrates and reduce Foxp3 expression level in Tregs. Our result support testing of tumor cell vaccine for Renal cell carcinoma in a clinical settings and also suggest the tumor and Tregs dual targeting vaccine may have better success rate in patients with established disease.
- Anatomy and Physiology
- Medicine and Medical Research